Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer

Background Mutations of AT‐rich interactive domain 1 ( ARID1A ) have been associated with a worse outcome after intravesical treatment with bacille Calmette‐Guérin in patients with non–muscle‐invasive bladder cancer (NMIBC). Loss of ARID1A protein expression in urine cytology may serve as an indication of an ARID1A mutation. Therefore, the authors examined the expression of ARID1A in urine cytology and histological specimens of bladder cancer...